+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Rhinovirus Infections - Pipeline Review, H1 2020

  • ID: 5017433
  • Drug Pipelines
  • March 2020
  • Region: Global
  • 58 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Apollo Therapeutics LLC
  • Biological Mimetics Inc
  • Gilead Sciences Inc
  • Meissa Vaccines Inc
  • PrEP Biopharm Ltd
  • Romark Laboratories LC
  • MORE
Rhinovirus Infections - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Rhinovirus Infections - Pipeline Review, H1 2020, provides an overview of the Rhinovirus Infections (Infectious Disease) pipeline landscape.

Rhinoviruses are common cause of the common cold. The virus can spread through droplets in the air when someone who is sick coughs, sneezes or talks. Symptoms include sore throat, runny nose, sneezing, fatigue, headache and loss of appetite. Risk factors include age and weakened immune system. Treatment includes pain relievers and decongestant medications.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Rhinovirus Infections - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Rhinovirus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rhinovirus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rhinovirus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 7 and 7 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Rhinovirus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rhinovirus Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Rhinovirus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rhinovirus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rhinovirus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rhinovirus Infections (Infectious Disease)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rhinovirus Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rhinovirus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Apollo Therapeutics LLC
  • Biological Mimetics Inc
  • Gilead Sciences Inc
  • Meissa Vaccines Inc
  • PrEP Biopharm Ltd
  • Romark Laboratories LC
  • MORE
  • Introduction
  • Report Coverage
  • Rhinovirus Infections - Overview
  • Rhinovirus Infections - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Rhinovirus Infections - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Rhinovirus Infections - Companies Involved in Therapeutics Development
  • Apollo Therapeutics LLC
  • AstraZeneca Plc
  • Biological Mimetics Inc
  • Collaborations Pharmaceuticals Inc
  • Enyo Pharma SA
  • Gilead Sciences Inc
  • Haplogen GmbH
  • Meissa Vaccines Inc
  • Polyrizon Ltd
  • PrEP Biopharm Ltd
  • Pulmotect Inc
  • Romark Laboratories LC
  • Sagimet Biosciences
  • Secarna Pharmaceuticals GmbH & Co. KG
  • ST Pharm Co Ltd
  • Symmune Therapeutics LLC
  • Viravaxx AG
  • Rhinovirus Infections - Drug Profiles
  • Antisense Oligonucleotide for Rhinovirus Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BNT-014 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drugs for Enterovirus Infections and Rhinovirus Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drugs for Rhinovirus and Coxsackievirus Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • human rhinovirus (polyvalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • nitazoxanide CR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OBR-5340 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PL-402 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Polymer for Viral Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PrEP-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PUL-042 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rhinovirus vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Rhinovirus Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Rhinovirus Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit 3C Protease for Rhinovirus Infection - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit PLA2G16 for Rhinovirus Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SYM-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TVB-3567 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VXX-003 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Rhinovirus Infections - Dormant Projects
  • Rhinovirus Infections - Discontinued Products
  • Rhinovirus Infections - Product Development Milestones
  • Featured News & Press Releases
  • May 10, 2017: Meissa announces award of NIH SBIR grant to support development of multivalent human rhinovirus vaccine candidate
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
List of Tables
  • Number of Products under Development for Rhinovirus Infections, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Rhinovirus Infections - Pipeline by Apollo Therapeutics LLC, H1 2020
  • Rhinovirus Infections - Pipeline by AstraZeneca Plc, H1 2020
  • Rhinovirus Infections - Pipeline by Biological Mimetics Inc, H1 2020
  • Rhinovirus Infections - Pipeline by Collaborations Pharmaceuticals Inc, H1 2020
  • Rhinovirus Infections - Pipeline by Enyo Pharma SA, H1 2020
  • Rhinovirus Infections - Pipeline by Gilead Sciences Inc, H1 2020
  • Rhinovirus Infections - Pipeline by Haplogen GmbH, H1 2020
  • Rhinovirus Infections - Pipeline by Meissa Vaccines Inc, H1 2020
  • Rhinovirus Infections - Pipeline by Polyrizon Ltd, H1 2020
  • Rhinovirus Infections - Pipeline by PrEP Biopharm Ltd, H1 2020
  • Rhinovirus Infections - Pipeline by Pulmotect Inc, H1 2020
  • Rhinovirus Infections - Pipeline by Romark Laboratories LC, H1 2020
  • Rhinovirus Infections - Pipeline by Sagimet Biosciences, H1 2020
  • Rhinovirus Infections - Pipeline by Secarna Pharmaceuticals GmbH & Co. KG, H1 2020
  • Rhinovirus Infections - Pipeline by ST Pharm Co Ltd, H1 2020
  • Rhinovirus Infections - Pipeline by Symmune Therapeutics LLC, H1 2020
  • Rhinovirus Infections - Pipeline by Viravaxx AG, H1 2020
  • Rhinovirus Infections - Dormant Projects, H1 2020
  • Rhinovirus Infections - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Rhinovirus Infections, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Apollo Therapeutics LLC
  • AstraZeneca Plc
  • Biological Mimetics Inc
  • Collaborations Pharmaceuticals Inc
  • Enyo Pharma SA
  • Gilead Sciences Inc
  • Haplogen GmbH
  • Meissa Vaccines Inc
  • Polyrizon Ltd
  • PrEP Biopharm Ltd
  • Pulmotect Inc
  • Romark Laboratories LC
  • Sagimet Biosciences
  • Secarna Pharmaceuticals GmbH & Co. KG
  • ST Pharm Co Ltd
  • Symmune Therapeutics LLC
  • Viravaxx AG
Note: Product cover images may vary from those shown
Adroll
adroll